GRI Bio, Inc. (GRI)
Nasdaq · Healthcare · Biotechnology
$1.91−2.55%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $4.2M
- 52-week range
- $1.36 – $64.12
- 52-week change
- −96.54%
- EPS (trailing)
- −$14.71
Fiscal year to Dec 2025
- Net income
- −$12.0M
- Diluted EPS
- −$121.80
- Free cash flow
- −$10.2M
From the company’s annual report on SEC EDGAR.
About GRI Bio, Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Headquarters: La Jolla, United States · 3 employees · gribio.com